Table 1.
Demographic, pathological and clinical characteristics of the various groups and subgroups used in the study (a) and adjusted odds ratio estimates with Wald confidence intervals (b)
| (a) Demographic, pathological and clinical characteristics of the various groups and subgroups used in the study | ||||||
|---|---|---|---|---|---|---|
| Variable | Days to AC from the date of definitive surgery | p value | ||||
| ≤ 30 days N (%) |
31–60 days N (%) |
61–90 days N (%) |
91–120 days N (%) |
> 120 days N (%) |
||
| BC subtype based on ER, PR and HER2 receptor status | < 0.001 | |||||
| ER+ PR- HER2-; ER- PR+ HER2-; ER+ PR+ HER2- (hormone positive/HER2 negative BC) | 36,863 (46.13) | 99,683 (56.31) | 32,563 (61.85) | 9116 (61.85) | 5203 (60.53) | |
| ER+ PR- HER2+ ; ER- PR+ HER2+ ; ER+ PR+ HER2+ (hormone positive/HER2 positive BC) | 15,506 (19.41) | 29,979 (16.93) | 8106 (15.40) | 2333 (15.83) | 1456 (16.94) | |
| ER- PR- HER2 + (hormone positive/HER2 negative BC) | 7082 (8.86) | 11,855 (6.70) | 3108 (5.90) | 907 (6.15) | 569 (6.62) | |
| ER- PR- HER2- (TNBC) | 20,453 (25.60) | 35,523 (20.06) | 8870 (16.85) | 2384 (16.17) | 1368 (15.91) | |
| Sex | 0.456 | |||||
| Male | 752 (0.94) | 1749 (0.99) | 550 (1.04) | 145 (0.98) | 85 (0.99) | |
| Female | 79,152 (99.06) | 175,291 (99.01) | 52,097 (98.96) | 14,595 (99.02) | 8511 (99.01) | |
| Age | < 0.001 | |||||
| Age 18–45 | 16,817 (21.05) | 27,931 (15.78) | 7652 (14.53) | 2121 (14.39) | 1260 (14.66) | |
| Age 45–60 | 35,761 (44.75) | 76,865 (43.42) | 22,070 (41.92) | 6225 (42.23) | 3608 (41.97) | |
| Age 60–70 | 19,214 (24.05) | 49,730 (28.09) | 15,531 (29.50) | 4313 (29.26) | 2485 (28.91) | |
| Age > 70 | 8112 (10.15) | 22,514 (12.72) | 7394 (14.04) | 2081 (14.12) | 1243 (14.46) | |
| Type of facility | < 0.001 | |||||
| Community Cancer Program | 40,521 (56.81) | 88,927 (54.04) | 25,011 (50.86) | 6881 (50.04) | 3879 (48.51) | |
| Academic/Research Program | 20,286 (28.44) | 52,028 (31.61) | 17,327 (35.23) | 4947 (35.98) | 3010 (37.64) | |
| Integrated Network Cancer Program | 10,515 (14.74) | 23,614 (14.35) | 6839 (13.91) | 1922 (13.98) | 1108 (13.86) | |
| Median income for the participants area of residence, 2008–2012 | < 0.001 | |||||
| < $48,000 | 27,693 (34.74) | 64,117 (36.30) | 20,621 (39.26) | 6068 (41.27) | 3629 (42.39) | |
| ≥ $48,000 | 52,032 (65.26) | 112,529 (63.70) | 31,897 (60.74) | 8636 (58.73) | 4931 (57.61) | |
| Insurance status | < 0.001 | |||||
| Not insured | 1672 (2.09) | 3776 (2.13) | 1398 (2.66) | 430 (2.92) | 318 (3.70) | |
| Private insurance | 54,110 (67.72) | 111,352 (62.90) | 30,319 (57.59) | 8041 (54.55) | 4300 (50.02) | |
| Government | 23,304 (29.16) | 59,947 (33.86) | 20,296 (38.55) | 6095 (41.35) | 3842 (44.70) | |
| Unknown | 818 (1.02) | 1965 (1.11) | 634 (1.20) | 174 (1.18) | 136 (1.58) | |
| Area of care in 2013 | < 0.001 | |||||
| Metro | 68,983 (86.33) | 152,116 (85.92) | 45,291 (86.03) | 12,786 (86.74) | 7569 (88.05) | |
| Urban | 10,921 (13.67) | 24,924 (14.08) | 7356 (13.97) | 1954 (13.26) | 1027 (11.95) | |
| Race | < 0.001 | |||||
| White | 65,825 (82.38) | 143,880 (81.27) | 40,848 (77.59) | 10,961 (74.36) | 6157 (71.63) | |
| African American | 9702 (12.14) | 23,164 (13.08) | 8645 (16.42) | 2874 (19.50) | 1862 (21.66) | |
| Others | 4377 (5.48) | 9996 (5.65) | 3154 (5.99) | 905 (6.14) | 577 (6.71) | |
| Analytic Stage Group (Assigned the value of Pathologic Stage Group. Clinical Stage Group is used if pathologic stage is not reported) | < 0.001 | |||||
| I | 25,116 (31.43) | 65,035 (36.73) | 19,547 (37.13) | 5240 (35.55) | 2952 (34.34) | |
| II | 37,986 (47.54) | 82,583 (46.65) | 24,078 (45.73) | 6705 (45.49) | 3740 (43.51) | |
| III | 16,802 (21.03) | 29,422 (16.62) | 9022 (17.14) | 2795 (18.96) | 1904 (22.15) | |
| Charlson Deyo Score | < 0.0001 | |||||
| 0 | 63,859 (86.83) | 149,249 (84.30) | 43,406 (82.45) | 11,903 (80.75) | 6945 (80.79) | |
| 1 | 8042 (10.93) | 22,885 (12.93) | 7385 (14.03) | 2222 (15.07) | 1267 (14.74) | |
| 2 | 1311 (1.78) | 3820 (2.16) | 1402 (2.66) | 443 (3.01) | 266 (3.09) | |
| ≥ 3 | 332 (0.45) | 1086 (0.61) | 454 (0.86) | 172 (1.17) | 118 (1.37) | |
| (b) Adjusted odds ratio estimates with Wald confidence intervals; with delay defined as getting AC > 60 days after the date of surgery | |||
|---|---|---|---|
| Patient demographic and tumor characteristics | Odds ratio estimate | 95% CI | |
| Age in years | |||
| 45–60 vs 18–45 | 1.113 | 1.078 | 1.150 |
| 60–70 vs 18–45 | 1.174 | 1.134 | 1.215 |
| > 70 vs 18–45 | 1.209 | 1.161 | 1.260 |
| 45–60 vs 60–70 | 0.948 | 0.928 | 0.969 |
| 45–60 vs > 70 | 0.920 | 0.893 | 0.949 |
| 60–70 vs > 70 | 0.970 | 0.943 | 0.999 |
| Race | |||
| African American vs Caucasian | 1.390 | 1.355 | 1.427 |
| Other races vs Caucasian | 1.124 | 1.081 | 1.168 |
| African American vs other races | 1.237 | 1.184 | 1.293 |
| Type of facility | |||
| Academic/Research Program vs Community Cancer Program | 1.276 | 1.251 | 1.301 |
| Integrated Network Cancer Program vs Community Cancer Program | 1.075 | 1.047 | 1.104 |
| Academic/Research Program vs Integrated Network Cancer Program | 1.186 | 1.154 | 1.220 |
| Insurance | |||
| Not insured vs private insurance | 1.435 | 1.354 | 1.521 |
| Not insured vs government | 1.113 | 1.049 | 1.181 |
| Not insured vs unknown | 1.169 | 1.059 | 1.291 |
| Private insurance vs government | 0.776 | 0.759 | 0.793 |
| Private insurance vs unknown | 0.815 | 0.751 | 0.884 |
| Government vs unknown | 1.050 | 0.967 | 1.141 |
| Median income for the participants area of residence, 2008–2012 | |||
| ≥ $48,000 vs < $48,000 | 1.071 | 1.042 | 1.101 |
| BC subtype based on ER/PR and HER2 receptor status | |||
| Hormone positive/HER2 negative BC vs TNBC | 1.611 | 1.569 | 1.654 |
| Hormone positive/HER2 positive BC vs TNBC | 1.235 | 1.197 | 1.274 |
| Hormone negative/HER2 positive BC vs TNBC | 1.202 | 1.153 | 1.253 |
| Hormone positive/HER2 negative BC vs hormone positive/HER2 positive BC | 1.305 | 1.272 | 1.339 |
| Hormone positive/HER2 negative BC vs hormone negative/HER2 positive BC | 1.340 | 1.290 | 1.393 |
| Hormone positive/HER2 positive BC vs hormone negative/HER2 positive BC | 1.027 | 0.985 | 1.071 |
| Analytic stage | |||
| Stage I vs II | 1.085 | 1.049 | 1.122 |
| Stage I vs III | 1.054 | 0.980 | 1.133 |
| Stage II vs III | 0.971 | 0.912 | 1.034 |
| Charlson Deyo total score | |||
| 1 vs 0 | 1.105 | 1.077 | 1.134 |
| 2 vs 0 | 1.258 | 1.191 | 1.329 |
| ≥ 3 vs 0 | 1.571 | 1.428 | 1.727 |
| 1 vs 2 | 0.878 | 0.829 | 0.931 |
| 1 vs ≥ 3 | 0.704 | 0.639 | 0.775 |
| 2 vs ≥ 3 | 0.801 | 0.719 | 0.893 |
BC breast cancer; AC adjuvant chemotherapy, ER estrogen receptor; PR progesterone receptor; HER2 human epidermal growth factor receptor 2